Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr… Read More
When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More
Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations two years ago, BMS now has more than 1,240 employees… Read More
Shape Therapeutics, a Seattle preclinical stage biotech company developing RNA editing and gene therapy technologies, has raised $112 million. The company’s RNA editing technologies are spun out of the lab… Read More
The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug. The news rattled investors’ confidence and sent… Read More
Henrik Andersen, head of biologics development at Bristol-Myers Squibb, knows what it’s like to be at a hot biotech when it’s scooped up by a much larger player. Andersen was… Read More
Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines. Alder… Read More
Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb (BMS) intends to buy Celgene, the parent company of Juno… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More
BELLEVUE, Wash. — Cancer treatments have improved astronomically in the past few decades. But as more patients overcome the disease, a different monster is rearing its head: financial toxicity. “Most… Read More
More than two years after a slate of patient deaths in a clinical trial, cancer immunotherapy company Juno Therapeutics is poised to settle a class action lawsuit over its handling of… Read More
In one of two recent Microsoft-to-Amazon moves, Brian Schultz, who has worked on-and-off at Microsoft since 1999, is now working on Amazon Web Services. According to his LinkedIn profile, Schultz is… Read More
Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s $9 billion acquisition by biotech giant Celgene, he told GeekWire… Read More
On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno Therapeutics, reached a deal to be acquired by biotech giant… Read More
GeekWire is going to Pittsburgh to cover the city’s tech renaissance, the challenges it faces as it grows and the dynamic in the city as it vies for Amazon’s HQ2.… Read More
When Celgene announced Monday that it will acquire Seattle-based biotech Juno Therapeutics for $9 billion, the development was a surprise to many — including some inside Juno itself, according to… Read More
Juno Therapeutics, the Seattle-based biotech company making cutting-edge cancer immunotherapy treatments, has reached a deal to be acquired by New Jersey-based Celgene for $9 billion, or $87 per share. Juno’s stock… Read More
New Jersey-based biotech giant Celgene is in talks to buy Seattle-based biotech Juno Therapeutics, according to a report in the Wall Street Journal. Juno’s stock rose more than 50 percent… Read More
Longtime Seattle tech design leader Hillel Cooperman has joined Oracle as the company’s senior vice president of user experience and design, according to his LinkedIn profile. GeekWire reached out to Cooperman… Read More
Daily deals company Groupon announced Tuesday that it has added a new face to its leadership board: Former Time and Amazon executive Colin Bodell has joined the company as its… Read More
Juno Therapeutics, the Seattle-based biotech company developing immunotherapy cancer treatments, unveiled promising new data from a study on its flagship cancer drug Wednesday. The company also beat analyst expectations with… Read More
CAR T immunotherapies — which genetically program immune cells to fight cancer — hold incredible promise for cancer patients who have run out of other options. But the treatments also… Read More
When you walk into Juno Therapeutics‘ new headquarters in Seattle, your eyes are immediately drawn to the view. The office’s 12th-floor reception desk offers a stunning panorama of the Olympic mountains,… Read More
Finding any kind of real estate in Seattle is pretty hard — and for a large, public biotech company like Juno Therapeutics, the search for a new home is particularly difficult.… Read More
It was an unusually busy week for news in the world of business, technology and science. Join us on this episode of GeekWire’s Week in Geek podcast to catch up… Read More
The Food and Drug Administration announced Wednesday that it has approved the first CAR T immunotherapy in the United States, a huge milestone for the group of breakthrough cancer treatments.… Read More
Seattle’s Juno Therapeutics, a biotech company developing cutting edge CAR T immunotherapies for cancer, faces a narrow field of competitors. Few other companies in the U.S. are working on CAR T… Read More
Seattle-based biotech company Juno Therapeutics beat analyst expectations in its second quarter revenue Thursday, reporting $21.3 million in revenue for the quarter compared to an analyst estimate of $15.82 million.… Read More
Dave Fetterman has had what you might call an illustrious career. He earned two degrees from Harvard, spent his first two years out of college as a software design engineer… Read More
Seattle-based biotech juggernaut Juno Therapeutics delivered mixed results in its 2017 quarter one earnings report Thursday — the first financial report from the company since it announced it was pulling the… Read More